[go: up one dir, main page]

JOP20180125B1 - صيغة صيدلانية سائلة ثابتة - Google Patents

صيغة صيدلانية سائلة ثابتة

Info

Publication number
JOP20180125B1
JOP20180125B1 JOP/2018/0125A JOP20180125A JOP20180125B1 JO P20180125 B1 JOP20180125 B1 JO P20180125B1 JO P20180125 A JOP20180125 A JO P20180125A JO P20180125 B1 JOP20180125 B1 JO P20180125B1
Authority
JO
Jordan
Prior art keywords
liquid pharmaceutical
stable liquid
pharmaceutical formulation
pharmaceutical formula
present
Prior art date
Application number
JOP/2018/0125A
Other languages
English (en)
Inventor
Joon Won Lee
Won Yong Han
Su Jung Kim
Jun Seok Oh
So Young Kim
Su Hyeon Hong
Yeon Kyeong Shin
Original Assignee
Celltrion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60787364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20180125(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltrion Inc filed Critical Celltrion Inc
Publication of JOP20180125A1 publication Critical patent/JOP20180125A1/ar
Application granted granted Critical
Publication of JOP20180125B1 publication Critical patent/JOP20180125B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير صيغة صيدلانية سائلة ثابتة محتوية على: جسم مضاد أو شظية رابطة مولد الضد منه؛ مادة خافضة للتوتر السطحي؛ سكر أو مشتق منه؛ ومحلول منظِّم. تتسم الصيغة الصيدلانية السائلة الثابتة وفقاً للاختراع الحالي بلزوجة منخفضة مع احتوائها على محتوى مرتفع من الجسم المضاد، وتتسم بثبات ممتاز في التخزين على المدى الطويل على أساس الثبات الممتاز في ظل ظروف التعجيل وظروف قاسية، ويمكن إعطاؤها تحت الجلد.
JOP/2018/0125A 2016-06-30 2017-06-28 صيغة صيدلانية سائلة ثابتة JOP20180125B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160083039 2016-06-30
PCT/KR2017/006855 WO2018004260A1 (ko) 2016-06-30 2017-06-28 안정한 액체 약제학적 제제

Publications (2)

Publication Number Publication Date
JOP20180125A1 JOP20180125A1 (ar) 2019-01-30
JOP20180125B1 true JOP20180125B1 (ar) 2022-09-15

Family

ID=60787364

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2018/0125A JOP20180125B1 (ar) 2016-06-30 2017-06-28 صيغة صيدلانية سائلة ثابتة

Country Status (41)

Country Link
US (3) US11951207B2 (ar)
EP (2) EP3479819B1 (ar)
JP (2) JP7082070B2 (ar)
KR (3) KR20180003452A (ar)
CN (1) CN109310628A (ar)
AU (2) AU2017287743C1 (ar)
CA (1) CA3028238C (ar)
CL (1) CL2018003662A1 (ar)
CO (1) CO2018013689A2 (ar)
CR (1) CR20180599A (ar)
CU (1) CU24561B1 (ar)
DK (1) DK3479819T5 (ar)
DO (1) DOP2018000290A (ar)
EA (1) EA201892653A1 (ar)
EC (1) ECSP18093651A (ar)
ES (1) ES2975782T3 (ar)
FI (1) FI3479819T3 (ar)
GE (1) GEP20217249B (ar)
HR (1) HRP20240426T1 (ar)
HU (1) HUE066142T2 (ar)
IL (1) IL263630B2 (ar)
JO (1) JOP20180125B1 (ar)
LT (1) LT3479819T (ar)
MA (1) MA45562B1 (ar)
MD (1) MD3479819T2 (ar)
MX (1) MX2018015960A (ar)
NI (1) NI201800139A (ar)
NZ (1) NZ770076A (ar)
PE (1) PE20190448A1 (ar)
PH (1) PH12018502670B1 (ar)
PL (1) PL3479819T3 (ar)
PT (1) PT3479819T (ar)
RS (1) RS65395B1 (ar)
SG (1) SG11201811320YA (ar)
SI (1) SI3479819T1 (ar)
SM (1) SMT202400143T1 (ar)
TN (1) TN2018000443A1 (ar)
TW (1) TWI736643B (ar)
UA (1) UA122610C2 (ar)
WO (1) WO2018004260A1 (ar)
ZA (1) ZA201808476B (ar)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
ES2933808T3 (es) 2017-01-11 2023-02-14 Celltrion Inc Fórmula líquida estable
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
WO2020060192A1 (ko) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 고농도의 계면활성제를 포함하는 트라스투주맙 안정화 액체 제제
CA3115747A1 (en) * 2018-10-10 2020-04-16 Astellas Pharma Inc. Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
CN111686247B (zh) * 2019-03-13 2022-07-29 苏州康乃德生物医药有限公司 包含人白介素-4受体α的抗体的液体组合物
US20230203147A1 (en) * 2019-03-18 2023-06-29 Alvotech Hf Aqueous formulations of tnf-alpha antibodies in high concentrations
KR20220003562A (ko) * 2019-04-23 2022-01-10 사노피 항-cd38 항체 및 제형
CN110095615A (zh) * 2019-05-27 2019-08-06 山东艾科达生物科技有限公司 一种测定超敏c反应蛋白含量的试剂盒
CN110585430B (zh) * 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
WO2021182874A1 (ko) * 2020-03-13 2021-09-16 삼성바이오에피스 주식회사 안정성이 증진된 액상 약제학적 조성물
US20230081265A1 (en) * 2020-04-06 2023-03-16 The Board Of Trustees Of The Leland Stanford Junior University Antibody formulation
CN114099424B (zh) * 2020-08-25 2025-03-14 越海百奥药业(绍兴)有限公司 一种重组免疫细胞因子的制剂
KR20240073051A (ko) * 2021-09-16 2024-05-24 주식회사 에이프로젠 항-TNFα 항체를 포함하는 약제학적 조성물
CN113940997B (zh) * 2021-12-21 2022-04-08 迈威(上海)生物科技股份有限公司 一种双特异性抗体的稳定制剂
CN118369117A (zh) * 2021-12-28 2024-07-19 山东先声生物制药有限公司 一种抗tnfr2抗体药物组合物
CN120322247A (zh) * 2022-12-09 2025-07-15 辛特里亚公司 用TNFα抗体治疗结节病的方法以及相关组合物和方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861335A (en) 1985-07-26 1989-08-29 Duoject Medical Systems Inc. Syringe
US5085642A (en) 1989-07-17 1992-02-04 Survival Technology, Inc. Conveniently carried frequent use autoinjector
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
WO1994011041A1 (en) 1992-11-19 1994-05-26 R G S.A.S. Di Rosaria Galli & C. Disposable auto-injector for prefilled syringes
DE4438360C2 (de) 1994-10-27 1999-05-20 Schott Glas Vorfüllbare partikelarme, sterile Einmalspritze für die Injektion von Präparaten und Verfahren zu ihrer Herstellung
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200710109B (en) * 2005-06-07 2009-10-28 Esbatech Ag Stable and soluble antibodies inhibiting TNFALPHA
CN102143976B (zh) 2008-06-25 2015-11-25 艾斯巴技术-诺华有限责任公司 抑制vegf的稳定和可溶的抗体
SG175188A1 (en) 2009-05-04 2011-11-28 Abbott Biotech Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
JO3533B1 (ar) * 2012-01-23 2020-07-05 Regeneron Pharma تركيبات ثابته تحتوي على مضادات حيوية مقاومة لـ ang2
EP2814468B1 (en) * 2012-02-16 2019-06-19 Santarus, Inc. Anti-vla1 (cd49a) antibody pharmaceutical compositions
WO2013164837A1 (en) 2012-03-07 2013-11-07 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
JP2015519382A (ja) * 2012-06-12 2015-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療用抗体のための医薬処方物
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
KR102362829B1 (ko) 2012-09-07 2022-02-15 코히러스 바이오사이언시즈, 인코포레이티드 아달리무맙의 안정한 수성 제형
FR2995214B1 (fr) 2012-09-10 2014-11-21 Adocia Solution a viscosite reduite de proteine a concentration elevee
CN104854133B (zh) 2012-10-12 2018-10-30 新加坡科技研究局 用于制备重组抗体治疗剂的最佳重链和轻链信号肽
JP2015536934A (ja) * 2012-10-25 2015-12-24 メディミューン，エルエルシー 安定した低粘度の抗体製剤
US20140161790A1 (en) * 2012-11-19 2014-06-12 Xencor, Inc. Engineered immunoglobulins with extended in vivo half-life
AU2014209994B2 (en) 2013-01-24 2017-03-16 Glaxosmithkline Intellectual Property Development Limited TNF-alpha antigen-binding proteins
JP6526025B2 (ja) 2013-10-16 2019-06-05 オンコバイオロジクス，インコーポレイティド 抗体安定性を増強する緩衝液製剤
CN104666242B (zh) * 2013-11-26 2018-01-02 信达生物制药(苏州)有限公司 一种稳定的抗TNF‑α抗体制剂及其用途
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
EP3125928A4 (en) * 2014-04-02 2017-11-29 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of adalimumab
EP3050557A1 (en) * 2014-05-23 2016-08-03 Ares Trading S.A. Liquid pharmaceutical composition
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
US20170360929A1 (en) 2014-12-23 2017-12-21 Pfizer Inc. Stable aqueous antibody formulation for anti tnf alpha antibodies
MX2017010400A (es) 2015-02-13 2017-11-28 Sanofi Sa Formulacion liquida estable para anticuerpos monoclonales.
AR118191A1 (es) 2019-02-28 2021-09-22 Celltrion Inc MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa

Also Published As

Publication number Publication date
PE20190448A1 (es) 2019-03-29
LT3479819T (lt) 2024-04-25
JOP20180125A1 (ar) 2019-01-30
EP4338752A2 (en) 2024-03-20
US20210000743A1 (en) 2021-01-07
MX2018015960A (es) 2019-03-21
IL263630B2 (en) 2023-06-01
MA45562A (fr) 2019-05-08
HRP20240426T1 (hr) 2024-06-21
EP4338752A3 (en) 2024-04-03
EP3479819A1 (en) 2019-05-08
JP2019525902A (ja) 2019-09-12
ES2975782T3 (es) 2024-07-15
FI3479819T3 (fi) 2024-04-17
AU2017287743B2 (en) 2020-01-30
KR20210042052A (ko) 2021-04-16
AU2020201249A1 (en) 2020-03-12
PL3479819T3 (pl) 2024-07-01
TWI736643B (zh) 2021-08-21
DK3479819T5 (da) 2024-09-09
EP3479819B1 (en) 2024-01-24
JP7082070B2 (ja) 2022-06-07
CU20180154A7 (es) 2019-08-06
KR102229274B1 (ko) 2021-03-18
EP3479819A4 (en) 2020-02-26
NI201800139A (es) 2019-03-25
NZ748101A (en) 2020-11-27
PH12018502670A1 (en) 2019-10-07
US20240269069A1 (en) 2024-08-15
GEP20217249B (en) 2021-04-26
NZ770076A (en) 2025-03-28
DK3479819T3 (da) 2024-04-15
JP2022122941A (ja) 2022-08-23
DOP2018000290A (es) 2019-02-15
CL2018003662A1 (es) 2019-03-15
KR20180097471A (ko) 2018-08-31
PH12018502670B1 (en) 2023-03-24
BR112018076377A2 (pt) 2019-03-26
EA201892653A1 (ru) 2019-05-31
HUE066142T2 (hu) 2024-07-28
CO2018013689A2 (es) 2019-01-18
CA3028238A1 (en) 2018-01-04
MA45562B1 (fr) 2024-05-31
AU2017287743A1 (en) 2018-11-22
CU24561B1 (es) 2022-01-13
AU2020201249B2 (en) 2021-07-15
TN2018000443A1 (en) 2020-06-15
UA122610C2 (uk) 2020-12-10
SMT202400143T1 (it) 2024-05-14
US11951207B2 (en) 2024-04-09
TW201806617A (zh) 2018-03-01
JP7405324B2 (ja) 2023-12-26
WO2018004260A1 (ko) 2018-01-04
SG11201811320YA (en) 2019-01-30
ZA201808476B (en) 2020-08-26
KR20180003452A (ko) 2018-01-09
AU2017287743C1 (en) 2020-10-01
SI3479819T1 (sl) 2024-06-28
IL263630A (en) 2019-01-31
CA3028238C (en) 2024-01-02
MD3479819T2 (ro) 2024-07-31
CR20180599A (es) 2019-04-09
ECSP18093651A (es) 2019-01-31
RS65395B1 (sr) 2024-04-30
US20240269071A1 (en) 2024-08-15
KR102397713B1 (ko) 2022-05-13
CN109310628A (zh) 2019-02-05
PT3479819T (pt) 2024-04-15

Similar Documents

Publication Publication Date Title
JOP20180125B1 (ar) صيغة صيدلانية سائلة ثابتة
MX382917B (es) Formulaciones de proteínas líquidas que contienen líquidos iónicos.
UA122478C2 (uk) Водна фармацевтична композиція, яка містить моноклональне антитіло до pd-l1
MX2016001018A (es) Composiciones estabilizadas de anticuerpos.
BR112018005349A2 (pt) preparação farmacêutica de anticorpo anti-pd-1 estável e sua aplicação em medicamentos
MX391067B (es) Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
EA201891344A1 (ru) Новые агонисты рецептора апелина и способы применения
EA201790649A1 (ru) Бензилзамещенные индазолы в качестве ингибиторов bub 1
AR098168A1 (es) Formulación estable de insulina glulisina
IN2014MU01248A (ar)
EA201590061A1 (ru) Фармацевтическая композиция
MX2016016148A (es) Preparacion de rocuronio con estabilidad mejorada.
UA117241C2 (uk) Бензоконденсовані гетероциклічні похідні, що використовуються як агоністи gpr120
MX376724B (es) Composicion oftalmica estable en almacenamiento.
MY194758A (en) Stable liquid pharmaceutical formulation
MX2016009458A (es) Solucion alcoholica estable de alprostadilo.
MX383557B (es) Formulaciones inyectables de paracetamol.
HK1226323A1 (en) Liquid protein formulations containing ionic liquids
HK1226310A1 (en) Liquid protein formulations containing water soluble organic dyes
HK1226318A1 (en) Liquid protein formulations containing organophosphates
TH1701002015A (th) องค์ประกอบวัคซีนที่การเกิดฟองลดลง